Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2009-03-25

Clinical Trial Update: Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder [Phase 3]

View source ↗

Summary

The document reports long-term safety and tolerability results from a Phase 3 trial of SR58611 in adults with major depressive disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SR58611

Snippet

Sponsor: Sanofi | Conditions: Major Depressive Disorders | Phase 3 | Status: COMPLETED